FDA Approves Lorlatinib for ALK+ NSCLC

November 2, 2018 – The FDA has granted lorlatinib an accelerated approval for the treatment of patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinase inhibitors (TKIs). Specifically, lorlatinib is approved for patients who have progressed on crizotinib and at least 1 other ALK inhibitor for metastatic disease; alectinib as the first ALK inhibitor therapy for metastatic disease; or ceritinib as the … (leggi tutto)